Treatment Response of Patients with Erythrodermic Psoriasis after Switching to Guselkumab.

Dermatol Ther (Heidelb) · 2021 · PMC7858723 · PMID 33400156

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

1 a, dotted line), there was a decreasing trend in PASI improvement through week 28; one of them was prescribed cyclosporine from week 12, and four patients were switched to other biologics (one switched to brodalumab at week 12; the other three switched to adalimumab, brodalumab, and ixekizumab, respectively, at week 28).

also in 47,180 other papers

showed a trendno p-value reported

Most of these patients showed a trend of continuous PASI improvement through week 36, after which the PASI score gradually became stable.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.